Phoenix Biotechnology, Inc. (PBI)'s Focus
While the prevention and treatment of human malignant disease remains PBI's primary focus, novel, patented extracts of Nerium oleander continue to reveal promising avenues of research showing activity against certain viral and neurodegenerative diseases.
2011 and 2009 ASCO
"Poster Discussion Group"
2009 SIO Intl' Conference
"Best of SIO"
"Technology Super Star"
New research findings presented in November at the Italian Cancer Society’s 61st annual meeting in Naples, Italy confirm the ability of Phoenix Biotechnology’s drug PBI-05204 to act synergistically with coadministration of temozolamide and radiotherapy to kill Glioblastoma Multiforme (GBM) in mice with orthotopically implanted human GBM cells. These data are currently being prepared for publication.
"The Botanical Glycoside Oleandrin Inhibits Human T-cell Leukemia Virus Type-1 Infectivity and Env-Dependent Virological Synapse Formation". Tetiana Hutchison, Laçin Yapindi, Aditi Malu, Robert A Newman, K Jagannadha Sastry and Robert Harrod. Journal of Antivirals & Antiretrovirals, (2019) Volume 11, Issue 3